Artios Pharma nabs $84 mln Series B

UK-based Artios Pharma Limited, a DNA damage response company developing treatments for cancer, has closed $84 million in Series B financing. Andera Partners and LSP led the round with participation from Pfizer Ventures, Novartis Venture Fund, Arix Bioscience, SV Health Investors, M Ventures, IP Group plc and AbbVie Ventures.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!